877397-65-4

Basic information

• Product Name: (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol
• Synonyms: BenzeneMethanol,2,6-dichloro-3-fluoro-a-Methyl-, (aS)-;(1S)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol;(S)-1-(2,6-dichloro-4-fluorophenyl)ethanol;(1S)-1-(2,6-Dichloro-3-fluorophenyl)ethane-1-ol;(aS)-2,6-Dichloro-3-fluoro-a-methyl-benzenemethanol;-1-(2,6-Dichloro-3-fluorophenyl);(S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol;(S)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol
• CAS NO: 877397-65-4
• Molecular Formula: C₈H₇Cl₂FO
• Molecular Weight: 209.04
• EINECS: 1308068-626-2
• Product Categories: Aromatic Ring;Chiral Compounds
• Mol File: 877397-65-4.mol
• Article Data: 32

Chemical Properties

• Boiling Point: 261.329 °C at 760 mmHg
• Flash Point: 111.848 °C
• Appearance: White/Solid
• Density: 1.407 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C
• PKA: 13.30±0.20(Predicted)
• CAS DataBase Reference: (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(877397-65-4)
• EPA Substance Registry System: (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(877397-65-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 877397-65-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 877397-65-4 differently. You can refer to the following data:
1. (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol is an intermediate in the synthetic preparation of Crizotinib (C785000), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor ( c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
2. (S) -1- (2,6-dichloro-3-fluorophenyl) ethanol(C8H7C12FO) is synthesized (R)-3-[l-(2, 6-dichloro-3-fluoro-benzene)- The key intermediate of ethoxy-5- (l-piperidine-4-hydroxy-1 hydrogen-pyrazole-4-hydroxy) -pyrimidine-2-indane. And (R)-3-[l-(2,6-dichloro-3-fluoro-benzene)-ethoxy-5-(l-piperidine-4-hydroxy-1 hydrogen-pyrazole-4-hydroxy) -Pyrimidine-2-indane is a small molecule kinase inhibitor for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) positive for anaplastic lymphohematokinase (ALK).
3. (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol is an intermediate in the synthetic preparation of Crizotinib (C785000), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.

InChI:InChI=1/C8H7Cl2FO/c1-4(12)7-5(9)2-3-6(11)8(7)10/h2-4,12H,1H3/t4-/m0/s1

Upstream product

• 108-22-5 Isopropenyl acetate 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 108-05-4 vinyl acetate 
• 141-78-6 ethyl acetate 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 877399-98-9 C₉H₉Cl₂FO₃S 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 
• 877397-67-6 1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 
• 877397-68-7 (1S)-1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 

Downstream Products

• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 877399-47-8 (R)-5-bromo-N,N-bis-(tert-butoxycarbonyl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridine-2-amine 
• 1448326-33-7 5-bromo-3-[1 (R)-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridin-2-ylamine 

Relevant articles and documents

Biotransformation of a crizotinib intermediate using a mutant alcohol dehydrogenase of Lactobacillus kefir coupled with glucose dehydrogenase

(S)-1-(2, 6-dichloro-3-fluorophenyl) ethanol, the key chiral intermediate of crizotinib, was prepared from 1-(2, 6-dichloro-3-fluorophenyl) ethanone using the alcohol dehydrogenases from Lactobacillus kefir (ADH-LK) with a tetrad mutant (ADH-LKM, F147L/Y1

Preparation method of deuterated crizotinib and derivatives thereof

The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.

Manganese-Catalyzed Enantioselective Hydrogenation of Simple Ketones Using an Imidazole-Based Chiral PNN Tridentate Ligand

A series of Mn(I) catalysts containing imidazole-based chiral PNN tridentate ligands with controllable 'side arm' groups have been established, enabling the inexpensive base-promoted asymmetric hydrogenation of simple ketones with outstanding activities (up to 8200 TON) and good enantioselectivities (up to 88.5percent ee). This protocol features wide substrate scope and functional group tolerance, thereby providing easy access to a key intermediate of crizotinib.